OncoHost Raises $35M in Series C Funding
- OncoHost, a Binyamina, Israel-based precision oncology company focused on advancing improved personalized cancer therapy, raised $35M in Series C funding
- The round was led by Alive Israel HealthTech VC, Leumi Partners, Menora Mivtachim, and OurCrowd
- Alive’s co-founder and general managing partner, Prof. Ari Shamiss, was recently named a new member of company’s board
- The company combines life-science research and advanced machine learning technology to develop personalized strategies for the success of cancer therapy
- The company continues to open additional clinical trial sites around the world and will be expanding its research to further cancer indications
- The company is set to commercial launch in the U.S. in the third quarter of 2022
